STERLINBIO

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

The Exchange has sought clarification from the Company with respect to news item captioned- ED charge sheet against Sterlite Biotech director In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been

The Exchange had sought clarification from the Company with respect to news dated 16-Jul-2018. The response from the Company is attached.

Sterling Biotech Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015'.

The Exchange has sought clarification from the Company with respect to attached news item. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of

The Exchange has sought clarification from the Company with respect to news item captioned- "Bank fraud - ED attaches Rs 4,701 cr assets of Gujarat pharma firm" In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any informatio

The Exchange has sought clarification from the Company with respect to news item captioned- "3 cos linked to bank fraud, bad debts face SFIO probe" In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has no

The Exchange has sought clarification from the Company with respect to news item captioned- "Andhra Bank moves NCLT against Sterling" In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announc

The Exchange has sought clarification from Sterling Biotech Limited with respect to recent news item captioned "ED charges bank former director in Rs.5,000cr scam involving Sterling Biotech Ltd (SBL) of the Sandesara Group of companies". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

The Exchange has sought clarification from Sterling Biotech Limited with respect to recent news item captioned "JSW Infra-Srei to buy Sterling Port in Dahej". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sterling Biotech Limited has submitted their response.

The Exchange has sought clarification from Sterling Biotech Limited with respect to recent news item captioned "JSW Infra-Srei to buy Sterling Port in Dahej". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

The Exchange has sought clarification from Sterling Biotech Limited with respect to recent news item captioned "Lenders plan to bring strategic investor in Sterling Port". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sterling Biotech Limited has submitted their response.

Significant increase in price has been observed in Sterling Biotech Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sterling Biotech Limited has submitted their response.

Significant increase in price has been observed in Sterling Biotech Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

The Exchange had sought clarification from the Company with respect to news item captioned "Rs 5k-cr loan default case: ED raids 7 Delhi locations of Sterling Biotech". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any in

The Exchange has sought clarification from the Company with respect to news item captioned ��Rs 5k-cr loan default case: ED raids 7 Delhi locations of Sterling Biotech��. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any

The Exchange has sought clarification from Sterling Biotech Limited with respect to recent news item captioned "Lenders plan to bring strategic investor in Sterling Port". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

The Exchange has sought clarification from Sterling Biotech Limited with respect to recent news item captioned "CBI registers FIR against Sterling Biotech". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sterling Biotech Limited has submitted their response.

The Exchange has sought clarification from Sterling Biotech Limited with respect to recent news item captioned "CBI registers FIR against Sterling Biotech". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

Sterling Biotech Limited has informed the Exchange that the Annual General Meeting of the members of the Company which is scheduled to be held on September 30, 2017 at 10.30 a.m. at Bhakti Kala Kshetra, International Society for Krishna Consciousness (ISKCON) Founder Acharya : His Divine Grace A.C. Bhaktivedanta Swami Prabhupada, Hare Krishna Land, Juhu, Mumbai - 400 049, Maharashtra, India, is postponed due to occurrence of certain unforeseen circumstances. A separate intimation about the date of Rescheduled Annual General Meeting will be made by the Company.

The Exchange had sought clarification from the Company with respect to news item captioned "CBI arrested Chetan Sandesara (Joint MD of Sterling Biotech) from Mumbai Airport in connection with Sandesara Group's Hawala scam." The response from the Company is attached.

The Exchange has sought clarification from the Company with respect to news item captioned "CBI arrested Chetan Sandesara (Joint MD of Sterling Biotech) from Mumbai Airport in connection with Sandesara Group's Hawala scam." In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this articl

Sterling Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on August 28, 2017.

Sterling Biotech Limited has informed the Exchange that the 'Register of Members' and 'Share Transfer Books' of the company will remain closed from the September 23, 2017 to September 30, 2017 (Both days inclusive) for the purpose of Annual General Meeting

Sterling Biotech Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2017

The Exchange has sought clarification from Sterling Biotech Limited with respect to recent news item captioned "CBI files FIR against Sterling Biotech; FIR files after suspicious transaction evidence allegedly found Fm Promoters residence". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sterling Biotech Limited has submitted their response.

The Exchange has sought clarification from Sterling Biotech Limited with respect to recent news item captioned "CBI files FIR against Sterling Biotech; FIR files after suspicious transaction evidence allegedly found Fm Promoters residence". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

Sterling Biotech Limited has submitted to the Exchange, the financial results for the period ended June 30, 2017.

Sterling Biotech Limited has informed the Exchange regarding Intimation about Search and seizure operations conducted by the Directorate of Enforcement.

Sterling Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2017.

Sterling Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

For and on behalf of Promoter and Promoter Group has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sterling Biotech Limited has submitted to the Exchange, the financial results for the period ended December 31, 2016.

Sterling Biotech Limited has informed the Exchange regarding Statement on Impact of Audit Qualifications - Annual Audited Results for the financial year of 15 months ended on March 31, 2016.

Sterling Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2016.

Sterling Biotech Limited has informed the Exchange that The Bank of New York Mellon, in its capacity as Depository to the Global Depositary Receipts ( GDRs") issued by the Company in the year 2003, have issued Termination Notice to the holders of GDRs intimating that they will terminate the Deposit Agreement dated October 01, 2003, and as a result the existing GDR facility will be terminated effective 5.00 p.m. (Eastern Time) on March 6, 2017.Kindly take the same on record.

Sterling Biotech Limited has submitted to the Exchange a copy voting results at the Annual General Meeting of the Company held on September 30, 2016 along with a copy of Scrutinizer's Report.

Sterling Biotech Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on September 30, 2016.

Sterling Biotech Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended June 30, 2016.

Sterling Biotech Limited has submitted to the Exchange a copy of Notice of Annual General Meeting of the company to be held on September 30, 2016 along a copy of Annual Report .

Sterling Biotech Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 23, 2016 to September 30, 2016(both days inclusive) for the purpose of Annual General Meeting of the Company is scheduled to be held on September 30, 2016

Sterling Biotech Limited has informed the Exchange that the meeting of the Board of Directors of the Company held on September 02, 2016, in view to raise the resources for the purpose of meeting general corporate purposes, Augment the long term resources for long term financial needs of the Company including payment of over dues and refinancing of the existing debt, Board of Directors of the Company has recommended issue of unlisted 8% Redeemable Cumulative Non Participating and Non Convertible Preference Shares carrying no voting rights subject to consent of members of the Company and oth

The Exchange has sought clarification from Sterling Biotech Limited with respect to recent news item captioned ''High court ordered RBI to investigate-Writ from High Court to Baroda's company on account of wrongful investment''. In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this

The Exchange has sought clarification from Sterling Biotech Limited with respect to recent news item captioned ''High court ordered RBI to investigate-Writ from High Court to Baroda's company on account of wrongful investment''. In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this

Sterling Biotech Limited has submitted to the Exchange the standalone financial results along with the Auditors Report for the period ended March 31, 2016.

Sterling Biotech Limited has informed the Exchange that the current Financial Year of the Company will be for 15 months commencing from January 2015 to March 2016.

Sterling Biotech Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended December 31, 2015.

Sterling Biotech Limited has informed the Exchange that regarding the Change in Financial Year.

Sterling Biotech Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2015.

Sterling Biotech Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2015.